| 查看: 732 | 回复: 0 | |||
ienjoysun银虫 (著名写手)
|
[交流]
FDA Releases Draft Guidance on Using the Inactive Ingredient Database
|
|
FDA Releases Draft Guidance on Using the Inactive Ingredient Database The draft guidance provides industry with a guide for using the database to assist in the development of drug products. Jul 10, 2019 By Pharmaceutical Technology Editors On July 10, 2019, FDA published draft guidance for public comment on the use of the Inactive Ingredient Database (IID). The guidance document provides information on how to use the IID when choosing inactive ingredients in the development of new drug products. The guidance also supports the agency’s efforts in the promotion of generic drugs as part of its Drug Competition Action Plan. The guidance also describes how the agency uses the IID to support the safety of inactive ingredients. It describes the structure of the IID, the process for adding ingredients to the IID, and how information is presented in the database, which gives users a better understanding of how to use the information. The IDD lists information on inactive ingredients used in FDA-approved drug products. Once an inactive ingredient is used in an approved drug for a specific route of administration it is not considered novel; therefore, the ingredient may not require extensive review by the agency the next time it is used in a new product. Source: FDA |
» 猜你喜欢
安徽医科大学-药理学求博导
已经有1人回复
丙酮酸激酶的抑制剂和激动剂
已经有1人回复
药理学论文润色/翻译怎么收费?
已经有227人回复
脓毒症(盲肠结扎)
已经有22人回复
广西医科大学基础医学院自身免疫病课题组招收基础医学、药学和生物学等专业的研究生
已经有7人回复
[学习资料分享] FAERS数据库的不良反应挖掘(频数法/贝叶斯法)
已经有1人回复
招收医学、基础医学类调剂研究生
已经有0人回复
是否属于脾肾阳虚证
已经有0人回复
广西医科大学基础医学院自身免疫病课题组招收基础医学相关专业的调剂研究生
已经有2人回复













回复此楼